- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01632202
Seprafilm Slurry in the Prevention of Uterine Scarring in Patients Undergoing Hysteroscopic Myomectomy (Seprafilm)
The Role of Seprafilm Bioresorbable Slurry in the Prevention of Intrauterine Synechiae in Patients Undergoing Hysteroscopic Myomectomy
Seprafilm is an FDA-approved temporary bioresorbable barrier that physically separates opposing tissue surfaces. The physical presence of the membrane separates adhesiogenic tissue while the normal tissue repair process takes place. When used in the abdominopelvic cavity, it has been shown to reduce the incidence of adhesions.
The intrauterine cavity is a potential space where the walls of the uterus are collapsed upon itself in the normal state. It has been demonstrated that the trauma of removing a submucosal fibroid with electrocautery exposes the uterus to great potential for intrauterine adhesions since the raw charred surface is directly opposed to the opposite endometrial surface. Previous studies have shown that the placement of hyaluronic acid in the intrauterine cavity after a myomectomy is not only safe, but also decreases the incidence of intrauterine adhesions.
The investigators hypothesize that by placing a slurry of Seprafilm in the intrauterine cavity and creating a temporary physical barrier between the walls of the uterus, that they will be able to prevent iatrogenic intrauterine adhesions. Given that approximately 24 to 48 hours after placement, the membrane becomes a hydrated gel that is slowly resorbed within one week, the investigators anticipate that the patient will have minimal to no discomfort; since no physical device is being left in the endometrial cavity, the uterus will not be contracting more than it does in its normal postoperative state.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The investigators will conduct a randomized controlled trial (RCT) involving patients at NewYork Presbyterian Hospital-Columbia University Medical Center and Weill Medical College of Cornell University. The investigators will enroll 328 pre- menopausal patients (>18years) with documented submucosal myomas undergoing hysteroscopic myomectomy with monopolar resection in this study.
The investigators anticipate that approximately 30% of the patients undergoing myomectomy will form intrauterine adhesions and that administration of the Seprafilm slurry will reduce the incidence to approximately 15%.
Patients will be queried on post-operative days 1, 7, and 30 for pain/discomfort and the degree of intrauterine adhesions will be assessed after the patient's second menses (75-90 days post procedure).
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10032
- Columbia University Medical Center
-
New York, New York, United States, 10021
- Weill Medical College of Cornell University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Reproductive aged women: Age 18-48 years old
- Non-pregnant
- Otherwise healthy
- Regular menstrual cycle
- Documented submucosal myomas (one or more)
- Undergoing hysteroscopic myomectomy
- Patients must have signed an informed consent.
Exclusion Criteria:
- Age < 18 or in menopause
- Undergoing a second uterine surgical procedure
- Other significant uterine pathology (including but not limited to adhesions, septae, or cancerous lesions)
- Hysteroscopic evidence of synechiae at the time of the procedure
- Surgeries complicated by excessive bleeding; defined by estimated blood loss > 100cc given that the presence of excessive bleeding may predispose a patient to the formation of intrauterine adhesions
- Surgeries complicated by uterine perforation
- Surgeries complicated by postoperative intrauterine infection given that infection may predispose a patient to the formation of intrauterine adhesions (If these patients received Seprafilm Slurry, they will continue to be followed for safety monitoring)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Seprafilm Slurry
The investigators hypothesize that by placing a slurry of Seprafilm in the intrauterine cavity and creating a temporary physical barrier between the walls of the uterus, that we will be able to prevent iatrogenic intrauterine adhesions.
Given that approximately 24 to 48 hours after placement, the membrane becomes a hydrated gel that is slowly resorbed within one week, we anticipate that the patient will have minimal to no discomfort; since no physical device is being left in the endometrial cavity, the uterus will not be contracting more than it does in its normal postoperative state.
|
Seprafilm Adhesion Barrier (membrane) is a sterile, bioresorbable, translucent adhesion barrier composed of two anionic polysaccharides, sodium hyaluronate (HA) and carboxymethylcellulose (CMC).
Together, these biopolymers have been chemically modified with the activating agent 1-(3-dimethylaminopropyl) -3- ethylcarbodiimide hydrochloride (EDC).
|
PLACEBO_COMPARATOR: Placebo
For those randomized not to receive Seprafilm slurry, a syringe will be filled with 25ml of sterile saline.
|
For those randomized not to receive Seprafilm slurry, a syringe will be filled with 25ml of sterile saline.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Presence of Iatrogenic Intrauterine Adhesions
Time Frame: 2- 3 months after surgery
|
Number of Subjects with iatrogenic intrauterine adhesions. Evidence of uterine scarring will be evaluated by a 3D sonohysterogram. A 3D sonohysterogram will be performed in the standard fashion in our ultrasound department by a blinded practitioner. The degree of adhesive disease will be scored by standard convention as:
|
2- 3 months after surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pregnancy Within 12 Months of Treatment
Time Frame: Up to 12 months after surgery
|
Number of pregnancies within 12 months of treatment.
In order to determine if Seprafilm helps improve pregnancy rates we will be conducting an additional follow-up phone call up to 12 months from the day of sonohysterogram.
In women who have wished to get pregnant we will ask if they have been trying to get pregnant and if they have gotten pregnant.
Participation in this follow up call is optional.
|
Up to 12 months after surgery
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Rogerio A Lobo, MD, Columbia University
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AAAF2293
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Intrauterine Adhesions
-
First Affiliated Hospital, Sun Yat-Sen UniversityUnknownIntrauterine AdhesionsChina
-
Capital Medical UniversityUnknownIntrauterine AdhesionsChina
-
Beijing Obstetrics and Gynecology HospitalUnknownThe Efficacy and Safety of the Dried Biological Amnion Graft in Patients With Intrauterine AdhesionsIntrauterine AdhesionsChina
-
University of CagliariAzienda Sanitaria Locale di Cagliari; Università degli Studi di Sassari; Azienda... and other collaboratorsUnknownIntrauterine Adhesions | Septate Uterus
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Institute of genetic development, Chinese Academy of Sciences; Institute of...CompletedInfertility | Intrauterine AdhesionsChina
-
Hua DuanRecruitingIntrauterine Adhesion | Database for Intrauterine Adhesion | Risk Factors for Intrauterine Adhesion | Risk Stratification and Prognostic AssessmentChina
-
The Fourth Affiliated Hospital of Zhejiang University...Recruiting
-
Rejoni Inc.CompletedIntrauterine AdhesionUnited States
-
Ain Shams Maternity HospitalCompletedIntrauterine AdhesionEgypt
-
Fu Xing Hospital, Capital Medical UniversityBeijing Tiantan HospitalUnknown
Clinical Trials on Seprafilm
-
Nihon UniversityCompleted
-
South East Area Health Education Center, Wilmington...New Hanover Regional Medical CenterTerminated
-
National Cancer Centre, SingaporeSingapore General HospitalTerminated
-
Abington Memorial HospitalTerminatedAdhesion Formation After Primary Cesarean DeliveryUnited States
-
University of British ColumbiaGenzyme, a Sanofi CompanyTerminatedEpithelial Ovarian CancerCanada, United States
-
Stan StawickiCompletedTrauma | Wounds and Injury | Open Abdomen | Abdominal AdhesionsUnited States
-
University of Maryland, BaltimoreGenzyme, a Sanofi CompanyWithdrawnOpen AbdomenUnited States
-
Genzyme, a Sanofi CompanyCompletedIntestinal Obstruction | Digestive System Surgical ProceduresUnited States, United Kingdom, Canada, Germany, Netherlands
-
Centre Leon BerardMinistry of Health, FranceCompletedColorectal CancerFrance
-
Gachon University Gil Medical CenterCompletedPatient Under Going Colorectal and Stomach Cancer SurgeryKorea, Republic of